AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35064012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG, TnT, and TTE.
Number of subjects: 253
Study 35064012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital diagnostic methods (ECG, TnT, TTE).
Number of subjects: 253
Study 35064012 — intervention group
Group type: EXPERIMENTAL
Intervention: RWMA as a diagnostic method.
Number of subjects: 253
Study 35064011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A1, dMMR/MSI-H)
Number of subjects: 290
Study 35064011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A2, MMRp/MSS)
Number of subjects: 290
Study 35064011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (combined cohorts)
Number of subjects: 290
Study 35064138 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance intervention (10-week balance exercise program)
Number of subjects: 95
Study 35064138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 35064249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anxiety (262 individuals, 7.0%)
Number of subjects: 3724
Study 35064249 — intervention group
Group type: COMPARATOR
Intervention: Patients without anxiety (3462 individuals, 93.0%)
Number of subjects: 3724
Study 35064449 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Adaptation group (n=130; 57% of participants)
Number of subjects: 224
Study 35064449 — intervention group
Group type: EXPERIMENTAL
Intervention: High Adaptation group (n=85; 37% of participants)
Number of subjects: 224
Study 35064449 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Low and High Adaptation)
Number of subjects: 224
Study 35064550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0
Study 35064550 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin 25 mg
Number of subjects: 0
Study 35064550 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study 35065038 — intervention group
Group type: EXPERIMENTAL
Intervention: CENTER-TBI frailty index score (range 0-30, standardized value range 0-1)
Number of subjects: 2993
Study 35065038 — intervention group
Group type: EXPERIMENTAL
Intervention: CENTER-TBI frailty index score for older adults (aged ≥65 years)
Number of subjects: 2993
Study 35065038 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK-TBI frailty index score (n=1667)
Number of subjects: 2993
Study 35065046 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC continued group
Number of subjects: 468
Study 35065046 — intervention group
Group type: COMPARATOR
Intervention: DOAC withheld group
Number of subjects: 468
Study 35065058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks for 2 cycles followed by surgical resection.
Number of subjects: 21
Study 35065290 — intervention group
Group type: EXPERIMENTAL
Intervention: Very High Repetitive Negative Thinking (VH-RNT)
Number of subjects: 150
Study 35065290 — intervention group
Group type: EXPERIMENTAL
Intervention: High Repetitive Negative Thinking (H-RNT)
Number of subjects: 150
Study 35065290 — intervention group
Group type: COMPARATOR
Intervention: Healthy Comparison Volunteers
Number of subjects: 150
Study 35065599 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 0.2 mg/kg of cisatracurium
Number of subjects: 10
Study 35065656 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational ketogenic nutrition adherence program (6 weeks)
Number of subjects: 9
Study 35065678 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-VR (immersive virtual reality version of the Box and Block Test)
Number of subjects: 45
Study 35065678 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-VR
Number of subjects: 45
Study 35065678 — intervention group
Group type: COMPARATOR
Intervention: BBT
Number of subjects: 45
Study 35065785 — intervention group
Group type: EXPERIMENTAL
Intervention: arsa-cel (gene therapy)
Number of subjects: 29
Study 35065801 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery collateral function assessment using radial artery pressure signals during manual occlusion.
Number of subjects: 0
Study 35065801 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual radial artery occlusion (RAO) to determine collateral flow index (CFI).
Number of subjects: 0
Study 35065941 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mechanical symptoms
Number of subjects: 100
Study 35065941 — intervention group
Group type: COMPARATOR
Intervention: Patients without mechanical symptoms
Number of subjects: 100
Study 35065975 — intervention group
Group type: EXPERIMENTAL
Intervention: High prevalence neighborhoods (HPN)
Number of subjects: 1238
Study 35065975 — intervention group
Group type: COMPARATOR
Intervention: Low prevalence neighborhoods (LPN)
Number of subjects: 1238
Study 35065975 — intervention group
Group type: EXPERIMENTAL
Intervention: Migration to rural areas
Number of subjects: 1238
Study 35066090 — intervention group
Group type: EXPERIMENTAL
Intervention: FVIII/PC
Number of subjects: 576
Study 35066175 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare-OA questionnaire
Number of subjects: 398
Study 35066531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-source photon-counting detector computed tomography (PCD-CT) with late enhancement (LE) scan using 100 mL contrast media.
Number of subjects: 30
Study 35066531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-source photon-counting detector computed tomography (PCD-CT) with late enhancement (LE) scan.
Number of subjects: 30
Study 35066633 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) software on ultrasound
Number of subjects: 901
Study 35066693 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenolanib 100 mg BID with paclitaxel 80 mg/m² and ramucirumab
Number of subjects: 27
Study 35066801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) for 104 weeks
Number of subjects: 0
Study 35067071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprimary percutaneous coronary intervention in women
Number of subjects: 18567
Study 35067071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprimary percutaneous coronary intervention in men
Number of subjects: 18567
Study 35067072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary CD34+ cell therapy
Number of subjects: 20
Study 35067230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (single loading dose of 4500 mg via enteric tube within 48 h of PASE onset)
Number of subjects: 12
Study 35067230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 12
Study 35067596 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-delivered mindfulness training (MT) for 30 minutes weekly for 8 weeks
Number of subjects: 33
Study 35067599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection with Neisseria gonorrhoeae
Number of subjects: 865
Study 35067599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection with Chlamydia trachomatis
Number of subjects: 865
Study 35067599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection with both Neisseria gonorrhoeae and Chlamydia trachomatis
Number of subjects: 865
Study 35067602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular Ocular Motor Screening (VOMS)
Number of subjects: 110
Study 35067602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory (DHI)
Number of subjects: 110
Study 35067602 — intervention group
Group type: COMPARATOR
Intervention: Functional Gait Analysis
Number of subjects: 110
Study 35067602 — intervention group
Group type: COMPARATOR
Intervention: Modified Illinois Agility Task
Number of subjects: 110
Study 35067602 — intervention group
Group type: COMPARATOR
Intervention: Revised High-Level Mobility Assessment Tool
Number of subjects: 110
Study 35067645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot intervention study (Pilot 1) with 49 participants
Number of subjects: 94
Study 35067645 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal observational study (Pilot 2) with 45 participants
Number of subjects: 94
Study 35067748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonication cultures
Number of subjects: 64
Study 35067748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue cultures
Number of subjects: 64
Study 35067748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration cultures
Number of subjects: 64
Study 35067748 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in antibiotic treatment
Number of subjects: 64
Study 35067817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative Er:YAG laser treatment (IncontiLase® procedure)
Number of subjects: 43
Study 35067817 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session maintenance treatments every 6 months
Number of subjects: 43
Study 35067817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative Er:YAG laser treatment
Number of subjects: 43
Study 35067914 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment, specific dosage and duration not available
Number of subjects: 0
Study 35068788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of autologous HSC and MSC infusion
Number of subjects: 5
Study 35068788 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administration
Number of subjects: 5
Study 35068788 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculturing MSCs with HSCs
Number of subjects: 5
Study 35068788 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoculture of HSCs and MSCs
Number of subjects: 5
Study 35068788 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture of HSCs and MSCs
Number of subjects: 5
Study 35069171 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week TT + VR intervention
Number of subjects: 96
Study 35069171 — intervention group
Group type: COMPARATOR
Intervention: 6-week TT + VR intervention
Number of subjects: 96
Study 35070353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-led physical activity resumption programme
Number of subjects: 60
Study 35070353 — intervention group
Group type: COMPARATOR
Intervention: Community-based physical activity resumption programme
Number of subjects: 60
Study 35070353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 35070367 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation
Number of subjects: 15
Study 35070788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 52
Study 35070795 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERA)
Number of subjects: 769
Study 35070795 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors
Number of subjects: 769
Study 35070795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin analogues
Number of subjects: 769
Study 35070795 — intervention group
Group type: EXPERIMENTAL
Intervention: sGC stimulator riociguat
Number of subjects: 769
Study 35070795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 769
Study 35070795 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management strategies
Number of subjects: 769
Study 35070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Citarinostat 360 mg once daily plus paclitaxel 80 mg/m²
Number of subjects: 20
Study 35070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Citarinostat 480 mg once daily plus paclitaxel 80 mg/m²
Number of subjects: 20
Study 35070991 — intervention group
Group type: EXPERIMENTAL
Intervention: Citarinostat 180 mg once daily plus paclitaxel 80 mg/m²
Number of subjects: 20
Study 35071653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (24 patients)
Number of subjects: 75
Study 35071653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose group (25 patients)
Number of subjects: 75
Study 35071653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (24 patients)
Number of subjects: 75
Study 35072046 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 263
Study 35072046 — intervention group
Group type: COMPARATOR
Intervention: Non-Black participants
Number of subjects: 263
Study 35072138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreens with MCE
Number of subjects: 19
Study 35072138 — intervention group
Group type: COMPARATOR
Intervention: Reference formulas (control)
Number of subjects: 19
Study 35072135 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic RASI therapy
Number of subjects: 3812
Study 35072135 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital RASI therapy
Number of subjects: 3812
Study 35072168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg maintenance weeks 0/4/16/28/40
Number of subjects: 20
Study 35072168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 20
Study 35072628 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccination
Number of subjects: 0
Study 35072628 — intervention group
Group type: COMPARATOR
Intervention: Mild infection
Number of subjects: 0
Study 35072628 — intervention group
Group type: COMPARATOR
Intervention: Severe infection
Number of subjects: 0
Study 35072628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 0
Study 35072722 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid injection
Number of subjects: 156
Study 35072722 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 156
Study 35072864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and dactinomycin (regimen EE4A)
Number of subjects: 8
Study 35073148 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Pertuzumab, and Docetaxel
Number of subjects: 45
Study 35073248 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35073571 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 30
Study 35073571 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 30
Study 35073727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 35073727 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab + ipilimumab
Number of subjects: 0
Study 35073769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermically stored amniotic membrane (HSAM)
Number of subjects: 10
Study 35073853 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome signature
Number of subjects: 0
Study 35073853 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome correlations
Number of subjects: 0
Study 35073853 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosamples
Number of subjects: 0
Study 35073853 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 antigen and antibody associations
Number of subjects: 0
Study 35073864 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with Plasmodium falciparum sporozoites NF54 strain (Sanaria® PfSPZ Challenge)
Number of subjects: 142
Study 35073864 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 142
Study 35073864 — intervention group
Group type: COMPARATOR
Intervention: Observational field-based studies in children
Number of subjects: 142
Study 35073935 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer maternal telomere length
Number of subjects: 950
Study 35073935 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher paternal age
Number of subjects: 950
Study 35073963 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) prescribed based on pattern differentiation in addition to conventional medication (ConM)
Number of subjects: 160
Study 35073963 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication (ConM) only
Number of subjects: 160
Study 35073985 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable hydration monitor (Sixty device), worn at every dialysis session and nocturnally over a three-week period.
Number of subjects: 20
Study 35073985 — intervention group
Group type: COMPARATOR
Intervention: Bioimpedance measurements using the Fresenius body composition monitor, performed on 4 occasions as a comparator.
Number of subjects: 20
Study 35074000 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted, social support-based diabetes group visit model
Number of subjects: 14
Study 35074020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (840 kcal/day) for weight loss and diabetes remission, 12-week duration, monitored weekly for weight and blood glucose.
Number of subjects: 0
Study 35074020 — intervention group
Group type: COMPARATOR
Intervention: Adapted online protocol with self-measurement at home and mobile app for data entry.
Number of subjects: 0
Study 35074072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib-rituximab induction (12 cycles; oral ibrutinib 560 mg daily and intravenous rituximab 375 mg/m2)
Number of subjects: 131
Study 35074072 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HCVAD (four cycles)
Number of subjects: 131
Study 35074072 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment approach (ibrutinib-rituximab followed by R-HCVAD)
Number of subjects: 131
Study 35074459 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 287
Study 35074532 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic fatty liver disease fibrosis score (NFS)
Number of subjects: 3207
Study 35074532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis-4 index (FIB-4)
Number of subjects: 3207
Study 35074532 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Liver Fibrosis test (ELF)
Number of subjects: 3207
Study 35074532 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness by vibration-controlled transient elastography
Number of subjects: 3207
Study 35074631 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-based resistive index (RI)
Number of subjects: 118
Study 35074631 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-quantitative evaluation of renal perfusion using color-Doppler (SQP)
Number of subjects: 118
Study 35074651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib and cetuximab combined with FOLFIRI
Number of subjects: 21
Study 35074812 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline genetic variants
Number of subjects: 0
Study 35074812 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical data from the SCCR
Number of subjects: 0
Study 35075288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy by autologous CD34+ cells, details on dosage and duration not available.
Number of subjects: 0
Study 35075289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy
Number of subjects: 8
Study 35075361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 12
Study 35075363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sambiloto extract
Number of subjects: 73
Study 35075363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 35075450 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA BNT162b2 vaccine (two doses)
Number of subjects: 404
Study 35075526 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared mental models (SMMs) of the current situation
Number of subjects: 58
Study 35075526 — intervention group
Group type: EXPERIMENTAL
Intervention: SMMs of team resources
Number of subjects: 58
Study 35075526 — intervention group
Group type: EXPERIMENTAL
Intervention: VATSAT score
Number of subjects: 58
Study 35075526 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 58
Study 35075526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of intra-operative bleeding
Number of subjects: 58
Study 35076026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ) loss progression rate
Number of subjects: 66
Study 35076026 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer nuclear layer (ONL) thinning
Number of subjects: 66
Study 35076026 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner segment (IS) thinning
Number of subjects: 66
Study 35076026 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer segment (OS) thinning
Number of subjects: 66
Study 35076026 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-phenotype analysis
Number of subjects: 66
Study 35076282 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (300-mg intramuscular injection)
Number of subjects: 0
Study 35076282 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (prophylactic administration)
Number of subjects: 0
Study 35076282 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (therapeutic administration)
Number of subjects: 0
Study 35076282 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442
Number of subjects: 0
Study 35076300 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-based PET/CT with fluorine 18-DCFPyL as a radiotracer
Number of subjects: 1289
Study 35076329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (Durysta)
Number of subjects: 0
Study 35076329 — intervention group
Group type: COMPARATOR
Intervention: Topical hypotensive regimens
Number of subjects: 0
Study 35076335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 14
Study 35076703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamorolone (≥2.0 mg/kg/d)
Number of subjects: 46
Study 35076703 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids (DNHS and NSUK)
Number of subjects: 46
Study 35076712 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of T1D ≥50 years
Number of subjects: 165
Study 35076812 — intervention group
Group type: EXPERIMENTAL
Intervention: abemaciclib plus anastrozole
Number of subjects: 222
Study 35076812 — intervention group
Group type: COMPARATOR
Intervention: anastrozole or abemaciclib alone
Number of subjects: 222
Study 35076863 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Partnerships to Prevent Cancer (HELP PC) intervention facilitated by community health workers (CHWs)
Number of subjects: 0